These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36255040)

  • 41. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.
    Casulo C; Day B; Dawson KL; Zhou X; Flowers CR; Farber CM; Hainsworth JD; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
    Ann Oncol; 2015 Nov; 26(11):2311-7. PubMed ID: 26362568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine-Rituximab.
    Rajabto W; Harahap AS; Putra HN
    Acta Med Indones; 2024 Apr; 56(2):249-252. PubMed ID: 39010773
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does Up-front Autologous Stem-Cell Transplantation at First Relapse Improve Outcome in Transplant-Eligible Follicular Lymphoma Patients Whose Disease Relapses Within 24 Months?
    Yahya A; Radhwi O; Sobh M; Huebsch L; MacDonald D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e423-e427. PubMed ID: 33558203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study.
    Zhou Y; Qin Y; He X; Liu P; Yang J; Zhou L; Zhou S; Gui L; Yang S; Zhang C; Shi Y
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):289-299. PubMed ID: 32970914
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Standard treatment and future perspectives for follicular lymphoma].
    Kameoka Y
    Rinsho Ketsueki; 2022; 63(9):1135-1144. PubMed ID: 36198539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
    Lockmer S; Ren W; Brodtkorb M; Østenstad B; Wahlin BE; Pan-Hammarström Q; Kimby E
    Br J Haematol; 2020 Jan; 188(2):259-267. PubMed ID: 31423576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia].
    Nesterova ES; Kravchenko SK; Mangasarova YK; Baryakh EA; Misyurina AE; Vorobyev VI; Plastinina LV; Chernova NG; Kovrigina AM; Obukhova TN; Klyasova GA; Shevelev AA; Kostina IE; Gemdzhian EG; Gaponova TV; Vorobyev AI
    Ter Arkh; 2016; 88(7):62-71. PubMed ID: 27459617
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma.
    Paszkiewicz-Kozik E; Kulik J; Fabisiewicz A; Tysarowski A; Kraszewska E; Siedlecki JA; Walewski J
    Med Oncol; 2009; 26(1):16-21. PubMed ID: 18470485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
    Leonard JP; Trneny M; Izutsu K; Fowler NH; Hong X; Zhu J; Zhang H; Offner F; Scheliga A; Nowakowski GS; Pinto A; Re F; Fogliatto LM; Scheinberg P; Flinn IW; Moreira C; Cabeçadas J; Liu D; Kalambakas S; Fustier P; Wu C; Gribben JG;
    J Clin Oncol; 2019 May; 37(14):1188-1199. PubMed ID: 30897038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
    Wu JQ; Song YP; Su LP; Zhang MZ; Li W; Hu Y; Zhang XH; Gao YH; Niu ZX; Feng R; Wang W; Peng JW; Li XL; Ouyang XN; Wu CP; Zhang WJ; Zeng Y; Xiao Z; Liang YM; Zhuang YZ; Wang JS; Sun ZM; Bai H; Cui TJ; Feng JF
    Chin Med J (Engl); 2018 Aug; 131(15):1767-1775. PubMed ID: 30058572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
    Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
    Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
    Zinzani PL; Khuageva NK; Wang H; Garicochea B; Walewski J; Van Hoof A; Soubeyran P; Caballero D; Buckstein R; Esseltine DL; Theocharous P; Enny C; Zhu E; Elsayed YA; Coiffier B
    J Hematol Oncol; 2012 Oct; 5():67. PubMed ID: 23088650
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.
    Puvvada SD; Guillén-Rodríguez JM; Yan J; Inclán L; Heard K; Rivera XI; Anwer F; Mahadevan D; Schatz JH; Persky DO
    Oncology; 2018; 94(5):274-280. PubMed ID: 29471300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Follicular Lymphoma: Redefining Prognosis, Current Treatment Options, and Unmet Needs.
    Welaya K; Casulo C
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):627-638. PubMed ID: 31229159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.
    Miao Y; Hu S; Lu X; Li S; Wang W; Medeiros LJ; Lin P
    Hum Pathol; 2016 Dec; 58():72-77. PubMed ID: 27544800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
    Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
    Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date.
    Yilmaz U; Salihoglu A; Soysal T
    Drug Des Devel Ther; 2021; 15():3809-3820. PubMed ID: 34522085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
    Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
    Br J Haematol; 2016 Mar; 172(5):724-34. PubMed ID: 26729445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.